Physician profile
Robert S Smith
NPI 1518922277
$6,663.78
in general payments reported to CMS, 2019-2025
29 companies · $649 in 2025
The $649 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $766 · 2021: $1,325 · 2022: $1,443 · 2023: $997 · 2024: $814 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,459.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,350.12 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $857.46 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $815.78 | 2020-2025 | Vraylar, Synthroid, Ubrelvy |
| Novo Nordisk INC | $686.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $593.27 | 2020-2025 | Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $501.78 | 2019-2025 | Jardiance |
| Amgen INC. | $263.54 | 2019-2023 | Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $187.47 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $186.59 | 2021-2025 | Eliquis |
| Sanofi-Aventis U.S. LLC | $172.88 | 2019-2023 | |
| Astellas Pharma US INC | $172.18 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $171.52 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $137.52 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $71.02 | 2023-2024 | |
| Pfizer INC. | $66.63 | 2019-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $57.86 | 2023-2024 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $48.15 | 2020 | |
| Abbott Laboratories | $44.78 | 2022-2025 | Freestyle Libre 3 |
| Biogen, INC. | $39.61 | 2020 | |
| Seqirus USA INC | $33.85 | 2024 | Fluad, Flucelvax |
| Biohaven Pharmaceutical Holding Company Ltd. | $30.56 | 2022 | |
| Esperion Therapeutics, INC. | $27.94 | 2024-2025 | Nexletol |
| Allergan, INC. | $27.30 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $26.07 | 2024 | Unithroid |
| Phathom Pharmaceuticals, INC. | $20.42 | 2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $19.81 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $19.17 | 2022 | |
| Eisai INC. | $18.45 | 2022 | |
| Merck Sharp & Dohme LLC | $15.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.